🧬 Predict. Prevent. Protect: The APOL1 Proteomic Revolution

A fascinating new study in Nature Medicine describes a 9-protein APOL1 Proteomic Risk Score (APRS) capable of predicting kidney disease progression years before chronic kidney disease becomes clinically apparent.

Among individuals of African ancestry with APOL1 high-risk genotypes and preserved kidney function, APRS achieved a remarkable time-dependent AUC of ~86%, substantially outperforming traditional clinical scores and polygenic risk tools.

This work moves us closer to precision nephrology: identifying who is truly at risk, enriching clinical trials, and potentially guiding targeted therapies such as inaxaplin.

A powerful example of proteomics transforming static genetic risk into dynamic clinical prediction. 🔬🩺

Li C et al. Nature Medicine. 2026. doi:10.1038/s41591-026-04337